Prognosis
GSK Says HIV Shot Is Better than Daily Pills for Some Patients
- All patients in a trial have been offered the long-acting drug
- Drugmaker is betting on injectable treatments for HIV
Photographer: Norm Betts/Bloomberg
This article is for subscribers only.
GSK Plc’s long-acting HIV drug worked better than daily pills for some patients, especially those who have trouble adhering to a treatment schedule, according to a unit of the UK pharmaceutical company.
The positive interim results from an ongoing trial have resulted in all patients in the study being offered the long-acting injectable drug, said ViiV Healthcare, which specializes in HIV treatments and is majority owned by GSK. The drug, called Cabenuva, is injected as two shots every four weeks. It was approved in the US in 2021.